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This review focuses on the genetic features of psoriatic arthritis (PsA) and their relationship to phenotypic
heterogeneity in the disease, and addresses three questions: what do the recent studies on human leukocyte
antigen (HLA) tell us about the genetic relationship between cutaneous psoriasis (PsO) and PsA – that is, is PsO
a unitary phenotype; is PsA a genetically heterogeneous or homogeneous entity; and do the genetic factors
implicated in determining susceptibility to PsA predict clinical phenotype? We first discuss the results from
comparing the HLA typing of two PsO cohorts: one cohort providing the dermatologic perspective, consisting of
patients with PsO without evidence of arthritic disease; and the second cohort providing the rheumatologic
perspective, consisting of patients with PsA. We show that these two cohorts differ considerably in their
predominant HLA alleles, indicating the heterogeneity of the overall PsO phenotype. Moreover, the genotype of
patients in the PsA cohort was shown to be heterogeneous with significant elevations in the frequency of
haplotypes containing HLA-B*08, HLA-C*06:02, HLA-B*27, HLA-B*38 and HLA-B*39. Because different genetic
susceptibility genes imply different disease mechanisms, and possibly different clinical courses and therapeutic
responses, we then review the evidence for a phenotypic difference among patients with PsA who have inherited
different HLA alleles. We provide evidence that different alleles and, more importantly, different haplotypes
implicated in determining PsA susceptibility are associated with different phenotypic characteristics that appear to
be subphenotypes. The implication of these findings for the overall pathophysiologic mechanisms involved in PsA
is discussed with specific reference to their bearing on the discussion of whether PsA is conceptualised as an
autoimmune process or one that is based on entheseal responses.Introduction and concepts of pathogenesis
Psoriatic arthritis (PsA) is a heterogeneous disease with
diverse clinical and radiographic manifestations. However,
the specificity reported in development of the Classifica-
tion Criteria for Psoriatic Arthritis [1] strongly implies that
there are indeed common features which facilitate the
diagnosis of PsA. Nonetheless, patients often differ consid-
erably from one another in the type of their clinical mani-
festations, including whether or not they exhibit dactylitis,
enthesitis, asymmetric or symmetric sacroiliitis, or joint
deformity, but also in the presence and type of joint dam-
age on plain radiography. For example, in a recent cohort
study of patients with long-established PsA, 56% showed
no evidence of erosive disease after a mean follow-up of* Correspondence: rjw8@columbia.edu
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unless otherwise stated.19 ± 9 years, while the balance had erosive disease [2]. Di-
verse other varied radiographic features were present, in-
cluding features such as new bone formation, osteolysis
and ankylosis (Table 1). The basis for this heterogeneity
had not been adequately explained. In this review, the two
major hypotheses relating to disease pathogenesis are
discussed in light of recent data from studies of human
leukocyte antigen (HLA) genotypes in PsA [3,4] and a
study on the relationship of genotype to phenotype [2].
These hypotheses include the classical autoimmune basis
of disease and the concept that PsA starts at the enthesis
with microtrauma which then initiates innate immune
events. While not being entirely mutually exclusive, these
hypotheses present very different ideas about the initi-
ation/causation of PsA.
Psoriatic arthritis is an autoimmune disease
Several features in PsA suggest that an autoimmune
process may drive the disease. Firstly, susceptibility toral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Phenotypic heterogeneity in a cohort of 282
cases of psoriatic arthritis
Age 55 ± 12
Male gender 134 (47)
Family history of psoriasis (n = 280) 175 (63)
Family history of PsA (n = 280) 45 (16)
Age of onset of psoriasis 28 ± 14
Psoriasis duration (years) 27 ± 14
Age of onset of PsA 35 ± 13
PsA duration (years) 19 ± 9
Years between psoriasis and PsA 6 (0 to 14)
Psoriasis before PsA 184 (65)
PsA before psoriasis 45 (16)
Psoriasis and PsA at same time 52 (18)
Nail disease 244 (79)
Pitting 96 (34)
Onycholysis 155 (55)
Peripheral arthritis 280 (99)
Polyarthritis 258 (91)
Oligoarthritis 21 (8)






Joint deformitya 183 (65)
Joint fusiona 83 (29)
Erosionsa (n = 281) 123 (44)
Osteolysisa (n = 281) 41 (15)
Current PASI 1.2 (0.3 to 2.8)
Max PASI 3.8 (1.8 to 9.2)
Plaque psoriasis only 224 (79)
Psoriasis, nonplaque 59 (21)
Uveitis 9 (3)
Total on TNFi 176 (62)
Psoriasis requiring TNFi 32 (11)
PsA requiring TNFi 171 (60)
Number of TNFi, if on TNFi 1 (1 to 2; range 1 to 4)
Number of DMARDs 1 (1 to 2; range 0 to 5)
Data presented as mean ± standard deviation or n (%). DMARD, disease-modifying
antirheumatic drug; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; TNFi,
tumour necrosis factor inhibitor. aVariables used to construct the propensity score.
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patibility complex (MHC) genes [5]. Secondly, CD8+
T cells, which present antigen to molecules encoded by
HLA class 1 alleles, were shown to predominate in PsAsynovial fluid with a reversal of the CD4:CD8 ratio found
in rheumatoid arthritis (RA) [6]. Thirdly, CD8+ T cells in
synovial tissue and fluid obtained from PsA patients are
clonally expanded with a reduction in nonspecific T-cell
infiltration observed following methotrexate therapy [7,8].
Fourthly, the interesting observation in the setting of ad-
vanced HIV disease that both cutaneous psoriasis (PsO)
and PsA can occur more frequently and more severely in
the setting of CD4+ T-cell depletion suggests that persist-
ing memory-effector CD8+ T cells (and not CD4+ T cells
as in RA) drive the disease. Fifthly, PsA developed for the
first time after syngeneic bone marrow transplantation
from a PsO donor [9]. Finally, there is the response to
therapeutic agents directed at activated T cells (for ex-
ample, cyclosporine, DAB389IL-2 or alefacept), as well as
to effector pathways resulting from T-cell activation.
Given the above, one pathogenic hypothesis in PsA is
that molecules encoded by certain HLA class 1 alleles
bind self-peptides derived from proteins found in enthe-
seal and synovial sites. CD8+ T-cell clones specific for
these self-peptide–MHC complexes are inappropriately
activated, perhaps through the action of dendritic cells
and the activated state perpetuated by the continual sup-
ply of self-peptides. This is the classic explanation for an
autoimmune disease as a consequence of driver clones,
and one would expect to recognise one or a few immuno-
dominant T-cell receptor sequences in the inflammatory
infiltrate. Clonally expanded T cells have indeed been
demonstrated in PsA synovial fluid and tissue; however,
despite extensive earlier analysis of the T-cell clonotypes,
no evidence for an antigen driving this clonal expansion
common to all cases has been identified [8].
Other components of the immune system have an active
effector role in disease pathogenesis. Expression of MHC
class I chain-related A (MICA) and interleukin (IL)-15 can
lead to autoimmunity mediated by CD8+ effector T cells,
probably due to the capability of IL-15 to drive the expres-
sion of the natural killer group 2 member NKG2D [10]. A
more recent study demonstrated that PsA patients had up-
regulated IL-15 and MHC class I chain-related A (MICA)
in their affected synovial tissues [11]. This unique inflam-
matory environment enabled natural killer cell activation
and killing via NKG2D and cytosolic phospholipase cPLA2,
suggesting a destructive role for natural killer cells when
activated by environmental stress signals during the initi-
ation of PsA. Furthermore, as IL-15 could reproduce the
phenotype of joint natural killer cells from blood natural
killer cells, this study demonstrated that IL-15 is capable of
priming resting natural killer cells in tissues to the effector
phase. One additional possibility is that the clonally driven
CD8+ population contains an enriched population of IL-17
+CD8+ T cells in PsA synovial fluid that is not found in RA
synovial fluid, suggesting this population of T cells may be
worthy of further study [12].
Box 1. The most common human leukocyte antigen
alleles and haplotypes implicated in psoriatic arthritis
susceptibility and their location within the major
histocompatibility complex
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Ever since the hypothesis published in 1998 [13] and
through some elegant supporting anatomical and im-
aging studies [14], there has been growing support for
the concept that the origin of inflammation in spondy-
loarthritis including PsA is at the enthesis. Enthesitis
may be a prominent clinical feature at presentation in
up to 38% of PsA patients [15]. Anatomical studies have
shown that the enthesis is continuous with the joint struc-
ture [14] and that it also merges into the nail bed [16],
allowing for the development of concepts that link enthe-
seal involvement with prominent features of PsA, both
synovitis and nail dystrophic change. Furthermore, mag-
netic resonance imaging (MRI) studies have highlighted
bone marrow oedema at sites of entheseal attachment in
PsA, leading to the hypothesis that it may be microtrauma
at entheseal sites that in genetically susceptible individuals
leads to inflammation, as evidenced by bone marrow
oedema, which then spreads to secondarily involve struc-
tures such as the synovium or the nail. Immunohistologic
studies that have demonstrated both CD68+ macrophages
[17] and CD8+ T-cell infiltration [18] at sites of entheseal
inflammation add further weight to these concepts.
Review: genetics of psoriatic arthritis
One of the striking features of PsA is that as many as
50% of PsA patients have a family history that includes
one or sometimes multiple cases of PsA, PsO, or sero-
negative spondyloarthritis in their blood relatives, a likeli-
hood 40-fold greater than that of their unaffected spouses
[19-21]. Indeed, strong heritability has been demonstrated
across four generations in an elegant study [22]. This,
along with high twin concordance rates, establishes that
germline genes importantly contribute to the definition of
the predisposition to develop PsA. While the evidence that
genetics plays a major role in who develops PsA has been
present for many years, the identification of the genes re-
sponsible for conferring PsA has been a lengthy preoccu-
pation for a number of investigators that was limited by
the available technology, prevailing diagnostic criteria for
PsA and the study size.
Background findings
Because the highly polymorphic MHC genes have an im-
portant role in regulating immune responsiveness and
because PsA was considered an immune-mediated dis-
ease, MHC genes were the first candidates to be exam-
ined for a role in determining susceptibility to the
development of PsA, and accordingly this review focuses
on the contribution of HLA alleles. Association studies
of PsA with MHC genes began with Brewerton’s identifi-
cation of a significantly increased frequency of HLA-
B*27 in individuals with PsA using serologic methods,
where it was reported as strongly associated with axialdisease [23]. Subsequently, the dominant HLA allele as-
sociated with susceptibility to PsO was identified as
HLA-C*06:02, as it is now designated, although then it
was termed HLA-Cw6 and found to be present in ap-
proximately 60% of PsO cases. As anticipated from the
presence of PsO in PsA, PsA was also associated with an
elevated frequency of HLA-C*06:02 as first reported in a
study using serologic techniques by Murray and col-
leagues, where C*06:02 was identified in 34.6% of PsA
patients, 50% of PsO patients and 13.5% of controls [24].
In later studies, however, the proportion of serologically
defined HLA-C*06:02 varied from 60% to levels not sig-
nificantly different from the frequency in healthy con-
trols (15 to 20%). (For a more detailed summary of the
divergent results among these earlier reports, see [25].)
The earlier studies were notably limited by the impreci-
sion of the earlier serologic method of determining HLA
alleles, by comparing populations that varied in the fre-
quencies of certain HLA alleles and, perhaps most im-
portantly, by the classification criteria for PsA being
incompletely delineated. The main alleles and haplotypes
associated with PsO and PsA are summarised in Box 1.New data concerning psoriatic arthritis genetics
Because of the importance of more precisely determining
the role played by HLA alleles in PsA, using improved PsA
case ascertainment based on the Classification Criteria for
Psoriatic Arthritis (CASPAR) [1] and more accurate methods
of allele determination, we set out to compare the similar-
ities and differences in the frequency of HLA-B and HLA-C
locus alleles between PsO and PsA. We were particularly
interested in addressing the question of the genetic relation-
ship between PsO and PsA and asking whether PsA is a
genetically heterogeneous entity [4]. To achieve this, a PsO
cohort of 214 patients was assembled from individuals pre-
senting to a dermatologic clinic who were determined to be
FitzGerald et al. Arthritis Research & Therapy  (2015) 17:115 Page 4 of 11without features of arthritis, spondylitis or enthesitis through
examination by a rheumatologist. This cohort was com-
pared with a PsA cohort (n = 359) presenting to a rheuma-
tology clinic, in effect comparing the dermatologist’s
perspective of the PsO phenotype with that of the rheuma-
tologist, and asking whether the two perspectives were
equivalent. All patients in both cohorts belonged to the rela-
tively homogeneous Irish population and had Irish parents,
which diminished the problem of ethnic differences between
the cohorts.
The first point that emerged from the data analysis ad-
dressed the question of whether the distribution of the
HLA-C*06:02 alleles in the PsA cohort parallel that found
in the PsO cohort (Table 2). As a highly significant differ-
ence in the frequency of HLA-C*06:02 was found between
PsA and PsO (57.5% vs. 28.7%), we rejected the hypothesis
of genetic homogeneity of the PsO phenotype (P = 9.94 ×
10−12), although HLA-C*06:02 was moderately increased
in frequency in PsA. Figure 1 shows the differences in dis-
tribution of HLA-C*06:02:01 among the three cohorts of
PsA, PsO and healthy controls.
Since the frequency of HLA-C*06:02 was appreciably
decreased in the PsA cohort compared with that in the
PsO cohort, we then asked whether there are other HLA-
B alleles that are significantly increased in the Irish PsA
cohort. The data showed that HLA-B*27:05:02 and HLA-
B*39:01:01 were susceptibility alleles for PsA, but are not
high-risk alleles for PsO in the absence of arthritis, and
HLA-B*08:01 was associated with PsA susceptibility but
appears protective for PsO, being significantly reduced in
frequency in PsO (Table 3). This observation emphasised
the role of HLA-B alleles in PsA susceptibility, a finding
supported by the report from Okada and colleagues [26].
Taken together these findings demonstrate that PsA itself
is much more genetically heterogeneous than PsO and
provide further strong evidence for genetic heterogeneity
of the general PsO phenotype. In parallel with our ana-
lysis, another group studied this question with similar
methods and obtained almost identical results [3,4].
The number of different HLA alleles associated with
PsA susceptibility, and their differing frequencies be-
tween PsA cases and those with isolated cutaneous-only
PsO, are illustrated in Figure 2. These studies resolved
several important points of divergence in the literature
[25]. The genes associated with increased PsA suscepti-
bility (B*08:01, B*27:05, C*06:02, B*39:01 and B*38:01Table 2 Distribution of the HLA-C*06:02 and HLA-B*57:01 alle
cutaneous psoriasis
HLA allele PsA (%), n = 359 PsA versus control PsO (%), n = 214
B*57:01 18.4 2.5 (1.6 to 3.8) 31.3
C*06:02 28.7 1.8 (1.3 to 2.5) 57.5
Data presented as percentage or odds ratio (95% confidence interval). HLA, human(not illustrated in the figure)) were almost exclusively
present in seven classic ancestral haplotypes (for example,
B*08:01-C*07:01, B*27:05-C*02:02, B*27:05-C*01:02, B*37:
01-C*06:02, B*57:01-C*06:02, B*39:01-C*12:03 and B*38:
01-C*12:03). Apart from C*06:02, which is found on two
ancestral haplotypes (B*37:01-C*06:02 and B*57:01-
C*06:02), none of the other HLA-B alleles were associ-
ated with C*06:02. Additionally, B*44:02-C*05:01 and
B*44:03-C*16:01 were associated with significantly de-
creased susceptibility (not illustrated in the figure),
which indicates a protective effect. Table 4 presents the
contrasting molecular architecture and peptide binding
properties between two HLA-B molecules associated
with increased susceptibility and two that appear protect-
ive, being associated with significantly decreased suscepti-
bility [4]. The two molecules encoded by B*27:05:02 and
B*39:01:01 alleles have negatively charged glutamic acid in
the B pocket that preferentially binds the second amino
acid side chain (P2) of a peptide, as well as B*08:01 and
B*38:01, while the two molecules associated with de-
creased susceptibility have exactly the opposite charge
properties. This interpretation was supported by the re-
cent study from Okada and colleagues in a large cohort of
PsA patients using imputed HLA typing of HLA-B alleles
[26]. This suggests that the particular peptides bound by
HLA molecules play an important role in influencing the
development of the immune response underlying PsA.
Intriguingly, the B*39:06 allele, which differs by only a
few amino acids from B*39:01, was not associated with
PsA susceptibility, indicating a relatively precise mo-
lecular basis for susceptibility.
Different susceptibility genes imply different disease
mechanisms, and possibly a different clinical course and
therapeutic responses
While the genetic results have implications for who would
develop PsA, they formed the basis for asking whether the
different genotypes conferred different disease pheno-
types. A precedent for an effect of susceptibility alleles
on phenotype has been present since the initial study by
Brewerton and colleagues where HLA-B*27 was pro-
posed as being linked to the presence of axial disease in
PsA [23]. However, this association has been quite in-
consistent in subsequent studies [27-31]. Analogously,
HLA-C*06:02 was reported to be associated with fewer
involved or damaged joints [32].les in psoriatic arthritis does not parallel that found in
PsO versus control Control (%), n = 1,000 PsA versus PsO
5.71 (3.9 to 8.3) 7.4 0.30 (0.17 to 0.53)
6.61 (4.18 to 9.1) 19.3 0.26 (0.16 to 0.42)
leukocyte antigen; PsA, psoriatic arthritis; PsO, cutaneous psoriasis.
Figure 1 Distribution of HLA-C*06:02:01 among psoriatic arthritis,
psoriasis and healthy controls. Venn diagrams in each population
illustrate the approximate proportion of individuals that bear the
allele HLA-C*06:02:01. Ctrl, control; PsA, psoriatic arthritis; PsO,
cutaneous psoriasis.
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musculoskeletal involvement
The first clue in the present line of study that different
clinical phenotypes may be determined by different ge-
notypes was that the interval between the onset of PsO
and the development of PsA was influenced by the pa-
tient’s HLA type. The standard teaching is that PsA fol-
lows the onset of PsO by 10 to 15 years. We observed
that arthritis develops much closer to the appearance of
PsO in the HLA-B*27:05:02 or B*39:01:01 subset than in
the HLA-C*06:02 subset of PsA cases [4]. This indicated
that susceptibility genes were involved in determining
the time interval between PsO and PsA and that this
time difference is a genetically determined quantitative
trait. This suggested that the mechanism of genetic sus-
ceptibility in B*27:05:02 individuals resulted in similar
penetrance for musculoskeletal and skin disease, and that
they were roughly contemporaneous in onset. Indeed
nearly one-third of B*27:05:02 patients had the onset of
skin disease after the onset of musculoskeletal disease (that
is, PsA sine PsO). Conversely for HLA-C*06:02 patients,
the interval between skin disease and musculoskeletal dis-
ease was the expected lag of over a decade and HLA-
C*06:02 appeared to specify an effect that included highly
penetrant severe cutaneous disease and delayed milder
musculoskeletal disease with greatly reduced penetrance.Table 3 Additional HLA-B alleles that are significantly increas
HLA allele PsA (%), n = 359 PsA versus control PsO (%), n = 214
B*27:05 15.6 2.6 (1.7 to 4.2) 4.7
B*39:01 6.4 3.5 (1.6 to 7.6) 1.4
B*08:01 37.3 1.6 (1.2 to 2.0) 24.8
B*44:02 14.8 0.53 (0.36 to 0.80) 22.4
Data presented as percentage or odds ratio (95% confidence interval). HLA, humanGenetic influence on whether sacroiliitis is symmetrical or
asymmetrical
In a follow up to the original genetic paper, 282 patients
of the above described genetic study [4] who were avail-
able were extensively clinically and radiographically phe-
notyped, with the assessors completely blinded to the
previously reported HLA typing results. We first explored
univariate associations of HLA-B and HLA-C alleles and
haplotypes with at least 10 occurrences in the cohort,
previously associated with susceptibility with individual
clinical characteristics using the asymmetric two-tailed
Pearson chi-square method [2].
While ankylosing spondylitis is characterised by sym-
metrical sacroiliitis, in PsA sacroiliitis is more likely to
be asymmetric [33]. Table 5 presents data on whether the
finding of symmetric or asymmetric sacroiliitis by X-ray
imaging is associated with an HLA genotype. The table
shows that HLA-B*27:05:02 and both of its haplotypes
were strongly associated with symmetrical sacroiliitis. Sym-
metrical sacroiliitis and B*27:05 was male preponderant
(odds ratio = 11.91), resembling the findings in ankylosing
spondylitis and supporting current endeavours to group
the axial spondyloarthritis together. Both B*27 haplotypes
(B*27:05-C*01:02 and B*27:05:02-C*02:02:01) were equiva-
lently associated with symmetric sacroiliitis (Table 6).
In contrast, asymmetric sacroiliitis, the more prevalent
form of sacroiliitis in PsA, was not significantly associated
with B*27:05 but, rather, exhibited a strong association
with the more prevalent B*08:01-C*07:01 haplotype and
its constituent alleles. As a rough estimate of the effect of
these two haplotypes on the sacroiliitis phenotype, 24.4%
of those bearing B*27:05:02 developed symmetric sacroilii-
tis and 11.1% asymmetric sacroiliitis, while 2.9% of those
with B*08:01 developed symmetric sacroiliitis and 30.8%
asymmetric sacroiliitis.
Human leukocyte antigen associations of enthesitis
Enthesitis is often a striking feature of PsA. McGonagle
and colleagues, based on the finding of prominent bone
marrow oedema at sites of ligamentous attachment on
MRI scanning, proposed that PsA should be considered
an entheseal-based disease with secondary involvement
of synovial structures [13]. Subsequent studies confirmed
the finding of marrow oedema changes but showed that it
is non-PsA specific and is found in only a proportion ofed or decreased in the psoriatic arthritis cohort
PsO versus control Control (%), n = 1,000 PsA versus PsO
P = 0.23 5.5 3.77 (1.9 to 7.6)
P = 1 1.2 2.86 (1.1 to 7.6)
0.43 (0.25 to 0.76) 30.1 1.81 (1.6 to 6.5)
P = 0.7 24.6 0.60 (0.29 to 0.87)
leukocyte antigen; PsA, psoriatic arthritis; PsO, cutaneous psoriasis.
Figure 2 Certain HLA-B alleles in the psoriatic arthritis cohort are
significantly increased in frequency compared with their frequency
in cutaneous psoriasis and healthy controls. Venn diagrams in each
population illustrate the approximate proportion of individuals that
bear the alleles. Ctrl, control; PsA, psoriatic arthritis; PsO, psoriasis
where there is no arthritis.
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PsA in greater depth using a genetic approach, and found
that in univariate analysis the haplotype B*27:05-C*01:02
and its two constituent alleles, B*27:05 and C*01:02, were
strongly associated with the development of clinically
detectable enthesitis in PsA (Table 6). However, neither
the associations with the B*27:05:02-C*02:02:01 haplo-
type or its constituent alleles were similarly significant
for the presence of enthesitis. This association suggests
that a gene other than HLA-B*27:05, such as C*01:02:01
that is present on the B*27:05-C*01:02 haplotype, drives
the association with enthesitis or that a combination of
genes on that haplotype confers susceptibility to enthesitis.
Furthermore, enthesitis was not significantly associated
with the other major alleles implicated in PsA susceptibil-
ity. B*08:01 was not associated with enthesitis while enthe-
sitis was inversely associated with C*06:02 (odds ratio =
0.45, P = 0.045), indicating that this susceptibility allele is
protective for the presence of enthesitis. Accordingly, we
conclude that the genetic factors contributing to enthesitisTable 4 Amino acids in polymorphic sites of HLA-B
molecules associated with increased or decreased psoriatic
arthritis susceptibility and their contrasting effect on










B*27:05:02 Glu Cys Arg 3.18 (2.14 to 4.71)
B*39:01:01 Glu Cys Arg 3.74 (1.99 to 7.01)
B*44:02:01 Lys Ser Glu 0.53 (0.38 to 0.74)
B*44:03:01 Lys Ser Glu 0.47 (0.24 to 0.92)
Arg, arginine; Cys, cysteine; Glu, glutamic acid; Lys, lysine; Ser, serine. aData
presented as odds ratio (95% confidence interval).appear distinct from those operating in the development
of other features of PsA.
Synovial-based phenotypes are associated with B*08:01
In contrast, we found in univariate analysis that the
B*08:01:01-C*07:01:01 haplotype and its alleles are not
associated with enthesitis, but conversely were associated
with more synovial-based pathology such as joint deform-
ity and joint fusion. Joint deformity occurred in 46% of
those with B*08, and 86% of those with joint deformity had
B*08 (odds ratio = 2.3, P = 0.002). Joint fusion was found in
48.8% of those with B*08, and 39% of those with joint
deformity had B*08 (odds ratio = 2.0, P = 0.008). There was
no significant association of joint deformity or joint fusion
with B*27:05:02 or C*06:02:01.
Dactylitis exhibits a dual association with B*27:05 and
B*08:01
Intriguingly, dactylitis was strongly associated with the
presence of B*27:05 and particularly the B*27:05-C*01:02
haplotype (Table 7), but not the B*27:05-C*02:02 haplo-
type, mirroring the haplotype association of enthesitis.
However, alone among the phenotypic traits of severe
PsA, dactylitis was also positively associated with the
B*08:01-C*07:01 haplotype, implying the possibility that
a synovial-based process could also result in the pheno-
type of dactylitis, suggesting heterogeneity in the mechan-
ism underlying this trait. This is fully compatible with the
complexity of the process occurring in dactylitis [35-37],
including varying contributions of flexor tenosynovitis,
synovitis, enthesitis and more circumferential soft tissue
oedema. It would be of interest to determine whether
stratification of patients by either of these susceptibility al-
leles resulted in subgrouping patients with different types
of digital processes (for example, tenosynovitis/synovitis
vs. enthesitis).
Propensity to develop severe psoriatic arthritis
As an alternative approach to studying genotype–pheno-
type associations, we constructed a continuous variable
severity score to order the cohort based on the presence
of one or more of eight distinctive PsA phenotypic char-
acteristics that we considered would denote a more se-
verely involved patient, including enthesitis, symmetric
or asymmetric sacroiliitis, dactylitis, joint deformity, joint
erosion, joint fusion or osteolysis [2]. This score was used
to group patients into three tertiles according to their rank
in the severity score. As anticipated, the characteristics
that formed the basis of the score, with the single excep-
tion of enthesitis, were significantly more prevalent in the
group with a severity propensity score in the third tertile
compared with those in the first tertile. We then deter-
mined the associations of HLA-B and HLA-C alleles and
haplotypes with being in the top tertile of the PsA Severity





OR (95% CI) 3.65 (1.89 to 7.06)
C*01:02 21.60%
P value <0.000
OR (95% CI) 4.39 (2.02 to 9.57)
C*02:02 10%
P value 0.25
OR (95% CI) 1.67 (0.69 to 4.01)
B*27-C*01 17.50%
P value <0.000
OR (95% CI) 4.73 (1.96 to 11.41)
B*27-C*02 9.30%
P value 0.213
OR (95% CI) 1.80 (0.71 to 4.59)
CI, confidence interval; OR, odds ratio.
Table 5 Frequency of human leukocyte antigen allele or haplotype in forms of sacroiliitis
Marker Sacroiliitis Symmetrical sacroiliitis Asymmetrical sacroiliitis
B*08:01 50.70% 16.70% 62.70%
P value 0.006 0.066 <0.000
OR (95% CI) 2.15 (1.06 to 1.77) 0.323 (0.91 to 1.143) 3.8 (1.9 to 7)
B*27:05 23.20% 61.10% 9.80%
P value 0.059 <0.000 0.185
OR (95% CI) 1.92 (0.97 to 3.79) 10.63 (3.86 to 29.3) 0.52 (0.19 to 1.39)
C*01:02 18.6% 36.80% 11.80%
P value 0.027 <0.000 0.9
OR (95% CI) 2.32 (1.08 to 5.00) 5.57 (2.02 to 15.5) 1.06 (0.41 to 2.76)
C*02:02 10% 26% 4%
P value 0.42 0.002 0.26
OR (95% CI) 1.47 (0.57 to 3.76) 5.19 (1.67 to 16.1) 0.43 (0.09 to 1.9)
C*07:01 48.60% 15.8% 60.80%
P value 0.119 0.022 0.001
OR (95% CI) 1.53 (0.89 to 2.62) 0.25 (0.07 to 0.89) 1.73 (1.47 to 5.1)
B*08-C*07 47% 16% 59%
P value 0.026 0.057 <0.000
OR (95% CI) 1.86 (1.07 to 3.23) 0.31 (0.089 to 1.1) 3.18 (1.7 to 5.92)
B*27-C*01 14.30% 31.60% 7.80%
P value 0.064 0.001 0.78
OR (95% CI) 2.2 (0.94 to 5.15) 5.9 (2.0 to 17) 0.85 (0.28 to 2.61)
B*27-C*02 8.6% 26.3% 2.00%
P value 0.474 <0.000 0.134
OR (95% CI) 1.44 (0.53 to 3.95) 6.4 (2.0 to 20) 2.4 (0.03 to 1.8)
CI, confidence interval; OR, odds ratio.
FitzGerald et al. Arthritis Research & Therapy  (2015) 17:115 Page 7 of 11Propensity Score, developing an HLA risk score in
which +1 was awarded to the haplotypes B*27:05-C*02:02,
B*37:01-C:06:02 and B*08:01-C*07:01 while haplotypes in-
cluding B*44:02 or C*07:02:01 were awarded –1 and
HLA_B*57:01-C*06:02 was awarded 0. Since the genotype
of an individual contains two haplotypes, the risk score
ranged from –2 to +2, allowing evaluation of the contribu-
tion of the alleles on both maternal and paternal chromo-
somes to disease phenotype. Each unit increase in this
adjusted score, on average, was associated with a 168%
higher odds of being in the most severe PsA tertile (odds
ratio = 2.68, P <0.001). The additivity of the scores indi-
cated that B*27:05-C*02:02, B*37:01-C*06:02 and B*08:01-
C*07:01 were each equivalently associated together with a
more severe phenotype, and this was counterpoised by
the haplotypes associated with a zero or negative weight.
Intriguingly, these findings appear to suggest that the
presence of B*37 on a haplotype containing C*06:02
modifies the action of C*06:02, a point also raised by
Okada and colleagues [26].
However, the haplotype B*27:05-C*01:02, which was
associated with enthesitis in univariate analysis, was not
Table 7 Dactylitis is associated with both HLA-B*27:05 and B*08:01, but not HLA-C*06:02
HLA allele or haplotype Frequency (%) of HLA Odds ratio (95% CI) P value (two-sided)
With trait Without trait
B*27:05:02 21.3 9.8 2.5 (1.2 to 5.0) 0.009
B*27:05:02-C*01:02:01 12.0 5.3 2.5 (1.0 to 6.1) 0.05
B*27:05:02-C*02:02:02 8.7 4.5 2.0 (0.7 to 5.4) 0.2
B*08:01:01 42.7 30.3 1.7 (1.1 to 2.8) 0.03
B*08:01:01-C*07:01:01 42.0 29.3 1.8 (1.1 to 2.9) 0.03
C*06:02:01 25.3 33.8 0.7 (0.4 to 1.1) 0.1
B*44:02:01 9.3 22.0 0.37 (0.2 to 0.7) 0.003
B*44:02:01-C*05:01:01 8.7 18.0 0.43 (0.2 to 0.89) 0.02
B*44:03:01 6.0 15.2 0.36 (0.2 to 0.8) 0.012
B*44:03:01-C*16:01:01 3.3 9.8 0.3 (0.1 to 0.9) 0.03
CI, confidence interval; HLA, human leukocyte antigen.
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This indicates an unlinking of enthesitis with other ele-
ments that were studied in the PsA phenotype. Taken
together, these findings suggest that there are distinct
genetic factors contributing to enthesitis and these are
different from those operating in the development of
most other features associated with PsA.
Conclusions
Implications of newer findings on concepts of
genotype–phenotype relationships
There are several implications for the finding that cer-
tain HLA alleles and, most strikingly, particular haplo-
types that are implicated in the susceptibility to develop
PsA contribute differentially and often additively to the
magnitude of different traits comprising the phenotype
of PsA [2]. Despite the relatively large size of this cohort,
with 282 PsA cases clinically phenotyped and sequence-
based HLA typed to at least four digits, the study must
be considered exploratory and requires validation in differ-
ent ethnic groups, especially those with a greater admix-
ture of populations having different principal ancestral
haplotypes. In this way, the association of a particular allele
within the context of a given haplotype can be better deter-
mined. One anticipates that there will be different geno-
type–phenotype associations in a population that does not
include the major Northern European haplotypes such as
B*08:01-C*07:01, or those involving B*27. The disparate
phenotypic associations of different alleles/haplotypes
emphasise the distinct contribution of each different
susceptibility allele; however, the overarching common
features of all PsA patients may depend on the common
molecular architecture of susceptibility molecules (Table 5),
supported by the recent report of Okada and colleagues
[26]. Apart from the general mechanistic interpretation
of these genotype–phenotype associations that different
HLA alleles bind different self-peptides and drive differingautoimmune responses directed to distinct target mole-
cules, at this stage of knowledge it is not possible to
speculate on the precise molecular mechanisms that may
be operating to result in a different clinical phenotype. It
is possible that some inflammatory pathways will be more
analogous to those in PsO, while others may resemble
those of ankylosing spondylitis.
It is interesting to note that the newer genetic findings
are consistent with and appear to provide a molecular
explanation for the long-held clinical observations of Moll
and Wright [38], identifying entheseal predominant, syn-
ovial predominant and axial predominant as three of the
major forms of PsA, with each now found to have differ-
ing HLA associations. The findings summarised in this
review are also relevant to the discussion of pathogenic
mechanisms in PsA.
First, since different HLA molecules bind different pep-
tides, they probably imply the presence of distinct auto-
immune responses that are driving each of the phenotypes
separately associated with different HLA alleles. As a corol-
lary, the different peptides suggest that different proteins,
perhaps with a different cellular distribution, are targets of
these responses. Indeed, the finding that several different
HLA alleles confer susceptibility to PsA is an argument in
favour of an autoimmune hypothesis, since it directs atten-
tion to the different peptide binding properties of the mol-
ecules encoded by the susceptibility alleles.
Secondly, one anticipates that these responses may be
further distinguished by different predominant mecha-
nisms that use one or another cytokine, and so forth, per-
haps indicating that different drugs and biologics may be
effective in different genetic subsets. These data also raise
the possibility that there is a predominant type of target
tissue involved in each separate process. For example, it
may prove to be the case that whether you have HLA-
B*27:05 or HLA-B*08:01 will determine whether you have
symmetrical or asymmetrical sacroiliitis or whether you
Figure 3 Contribution of positive and negative risk alleles on
both chromosomes to psoriatic arthritis severity. An additive model
including all genotypes positively or negatively associated with
the propensity to develop severe psoriatic arthritis resulting in a
composite human leukocyte antigen (HLA) risk score.
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ant, or perhaps more synovial predominant. The question
of how these genotypes might result in a particular clinical
phenotype is unclear, but the work of Sherlock and col-
leagues would suggest that in a mouse model the develop-
ment of enthesitis may be linked to the presence of a
particular subset of T cells (IL-23R+, CD3+CD4−CD8−).
IL-23 elaborated at the enthesis through an effect of HLA-
B*27 on a haplotype encoding C*01:02 acts on this enthe-
seal cell population to elaborate inflammatory mediators
including IL-6, IL-17 and IL-22 [39]. Furthermore, their
data suggest that the presence of these entheseal resident
cells and their production of IL-22, which activates signal
transducer and activator of transcription 3-dependent
osteoblast-mediated bone remodelling, explains why dys-
regulation of IL-23 results in inflammation at this precise
anatomical site. This dysregulation of IL-23 is possibly
determined at a genetic level as a result of the response
of HLA-B*27 to microtrauma. Whether a similar model
applies to human disease, or even a proportion thereof
where there is prominent entheseal involvement (<30%
of PsA cases), has yet to be demonstrated.
However, the present findings argue against the enthe-
sitis hypothesis as a fundamental explanation for PsA in
all cases. The data summarised in Table 7, showing that
enthesitis is preferentially associated with the B*27:05-
C*01:02 haplotype, are not consistent with enthesitis be-
ing common to all PsA cases. Furthermore, in the devel-
opment of the propensity score (Figure 3) the presence
of enthesitis was not significantly associated with the other
traits comprising the score measuring the propensity for
severe PsA [2]. Furthermore, prominent entheseal involve-
ment on MRI is seen in only a minority of patients. Indeed,
one study found that MRI was not able to differentiate at
the group level between early PsA and RA on the basis of
entheseal-related disease [34]; however, a subgroup of PsA
patients had diffuse extracapsular enhancement (30%) or
diffuse bone oedema (20%). In addition and of interest
[40], HLA-B27 positivity in PsA and in axial spondyloar-
thritis defined a group of patients with more severe axial
bone marrow oedema on MRI that is probably related to
the classic ankylosing spondylitis phenotype, while HLA-
B27-negative PsA was likely to be reported as a negative
MRI examination result.
For the two-thirds of PsA patients that appear to have
a more synovial-predominant pattern of disease and who
are likely to be HLA-B*08:01, a more conventional auto-
immune basis of disease may apply. It is certainly pos-
sible in these subjects that molecules encoded by HLA
class 1 alleles are recognising self-peptides derived from
proteins found in synovial sites. CD8+ T-cell clones
specific for these self-peptides would be inappropriately
activated, perhaps by dendritic cells, and the activated
state perpetuated by the continual supply of self-peptides.These interactions may result in the elaboration of cyto-
kines such as interferon gamma or tumour necrosis factor
alpha, which in turn drive the inflammatory cascade.
Such an explanation of disease pathogenesis goes some
way to explain the consistent occurrence of dichotomous
therapeutic responses whereby skin and articular struc-
tures, for example, respond with different magnitude or
even direction to a given therapeutic agent (for example,
cyclosporine, ustekinumab, IL-17 inhibition). Using the
primary outcome measure of the American College of
Rheumatology 20% (ACR20) improvement in clinical
response, there is also a consistent degree of nonresponse
to any therapeutic agent (30 to 50%) – suggesting that
patients with certain clinical features will respond whereas
other patients with other features will not. These obser-
vations are consistent with the hypothesis that discreet
inflammatory pathways may operate across different tissue
compartments.
Finally, we would propose a testable hypothesis whereby
PsA can be considered to have at least four clinical pheno-
types – synovitis predominant, entheseal predominant,
axial predominant and mutilans – all determined by geno-
type. In each of these phenotypes and perhaps as a conse-
quence of the inflammatory events that occur following
the recognition of specific peptides presented by molecules
encoded by susceptibility allotypes and recognised by spe-
cific T-cell clonotypes, a different pattern of inflammation
FitzGerald et al. Arthritis Research & Therapy  (2015) 17:115 Page 10 of 11involving diverse immunoreactant molecules and medi-
ators such as cytokines may be unleashed that help to
determine clinical disease expression. As mentioned,
this is a testable hypothesis with RNA genome sequen-
cing and protein and cytokine profiling of very well-
characterised clinical phenotypic/genotypic groupings
likely to reveal consistent differences between the geno-
typic groupings.
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